Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
Market snapshot unavailable. Historical chart data may still be available.
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SVA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SVA, quarterly periods
Line item
Q2 FY2020 Jun 30, 2020
Q2 FY2019 Jun 30, 2019
Q4 FY2015 Dec 31, 2015
Q4 FY2014 Dec 31, 2014
Q4 FY2013 Dec 31, 2013
Q4 FY2012 Dec 31, 2012
Q4 FY2011 Dec 31, 2011
Q4 FY2010 Dec 31, 2010
Revenue
$52.33M
$64.05M
—
—
—
—
—
—
Cost of revenue
$7.56M
$6.09M
$0
$0
$0
$0
$0
$0
Gross profit
$44.77M
$57.95M
—
—
—
—
—
—
Selling, general and administrative
$29.79M
$30.19M
—
—
—
—
—
—
Research and development
$14.45M
$6.35M
—
—
—
—
—
—
Total operating expenses
$45.18M
$36.91M
—
—
—
—
—
—
Operating income
-$412K
$21.04M
—
—
—
—
—
—
Interest expense
-$373K
-$166K
—
—
—
—
—
—
Income before taxes
-$101K
$21.57M
—
—
—
—
—
—
Income taxes
$1.17M
$4.47M
—
—
—
—
—
—
Net income
-$1.27M
$17.1M
—
—
—
—
—
—
Net income attributable to common shareholders
-$5.26M
$10.66M
—
—
—
—
—
—
EBITDA
$1.2M
$22.28M
$0
$0
$0
$0
$0
$0
Basic earnings per share
-$0.05
$0.11
—
—
—
—
—
—
Diluted earnings per share
-$0.05
$0.09
—
—
—
—
—
—
Recent news
Company coverage with links to the original publishers.
The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.
Sinovac Biotech Ltd. (NASDAQ: SVA) is facing a crisis as its external auditor has resigned, leading to a delay in filing its annual report with the SEC. The company's current board is reviewing actions taken by the former board, causing uncertainty and disruption to the company's operations and governance.
The global respiratory disease vaccine market is expected to grow from $94.6 billion in 2024 to $101.56 billion by 2030, driven by factors such as the increasing prevalence of respiratory diseases, the aging population, and government vaccine mandates and recommendations.
The global influenza vaccine market is expected to grow from $6.7 billion in 2023 to $12.5 billion by 2032, driven by rising influenza cases, government initiatives, and the development of more effective vaccines.
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte Orientale Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte Orientale
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 8, 2025
$55.00
Jul 7, 2025
special
Stock splits
Historical share-structure events and their execution dates.